← Leaderboards
John Daniel Clarke
Washington State University
$3,673,284
Attributed
$3,673,284
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $685.3K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,673,284 · 5
By mechanism
R01$2,132,242 · 1
R00$714,616 · 1
R21$420,750 · 1
R56$222,910 · 1
K99$182,766 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington State University
Same institution · by research overlap
- Douglas E Soltis$4,574,057
- Pamela S Soltis$11,710,596
- Kenneth Mopper$2,019,783
- James T Nguyen$76,566
- Frank J Loge$1,323,136
Others in their field
Top investigators on “Hepatocyte”
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Mark A Kay · Stanford University$31,244,013
- Charles M. Rice · Rockefeller University$27,314,965
- Stephen Lev Hoffman · Sanaria, Inc.$26,407,941
- Stefan H.i. Kappe · Seattle Children'S Hospital$25,211,763
- Michael H Nathanson · Yale University$22,903,080
Research focus
HepatocyteIn VitroIn VivoUptakePathway InteractionsLiver DiseasesMediatingExposure ToCellsNonalcoholic SteatohepatitisNational Institute Of Environmental Health SciencesAnimalsLiverToxinCyanoginosin LrRattusCyanobacteriumDietScientistBaseNon-Alcoholic Fatty Liver DiseasePositioning AttributeHepaticPharmaceutical Preparations
Grant awards (13)
Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis$379,765
R01 · FY2025 · ES · contact PI
Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis$384,492
R01 · FY2024 · ES · contact PI
Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis$420,750
R01 · FY2023 · ES · contact PI
Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis$491,425
R01 · FY2022 · ES · contact PI
Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis$455,810
R01 · FY2021 · ES · contact PI
Enteric and hepatic transporter mechanisms for pharmacokinetic natural product-drug interactions$229,500
R21 · FY2021 · AT · contact PI
Risk of xenobiotic-drug interactions in chronic disease$222,910
R56 · FY2020 · AT · contact PI
Enteric and hepatic transporter mechanisms for pharmacokinetic natural product-drug interactions$191,250
R21 · FY2020 · AT · contact PI
Microcystin-LR toxicity in nonalcoholic steatohepatitis$237,186
R00 · FY2019 · ES · contact PI
Microcystin-LR toxicity in nonalcoholic steatohepatitis$228,430
R00 · FY2018 · ES · contact PI
Microcystin-LR toxicity in nonalcoholic steatohepatitis$249,000
R00 · FY2017 · ES · contact PI
Microcystin-LR toxicity in nonalcoholic steatohepatitis$91,383
K99 · FY2016 · ES · contact PI
Microcystin-LR toxicity in nonalcoholic steatohepatitis$91,383
K99 · FY2015 · ES · contact PI